Literature DB >> 2573215

Serospecific protection of mice against intranasal infection with Bordetella pertussis.

A Robinson1, A R Gorringe, S G Funnell, M Fernandez.   

Abstract

The ability of purified serospecific agglutinogens from Bordetella pertussis to protect mice against intranasal infection has been examined. Immunization with agglutinogen 2 protected mice against infection with 1.2.0 or 1.2.3 serotypes of B. pertussis, whereas immunization with agglutinogen 3 protected mice against infection with all serotypes. More importantly immunization with serospecific agglutinogen resulted in immune selection so that organisms recovered following infection did not express the immunizing antigen. The results are consistent with the suggestions that protection of children with whole cell pertussis vaccine is to some extent serospecific and that agglutinogens should be considered as constituents of acellular pertussis vaccines.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573215     DOI: 10.1016/0264-410x(89)90193-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains.

Authors:  Olga Borisova; Svetlana Yu Kombarova; Nelli S Zakharova; Marjolein van Gent; Vladimir A Aleshkin; Isabella Mazurova; Frits R Mooi
Journal:  Clin Vaccine Immunol       Date:  2007-01-03

2.  The major fimbrial subunit of Bordetella pertussis binds to sulfated sugars.

Authors:  C A Geuijen; R J Willems; F R Mooi
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  Bordetella pertussis proteins dominating the major histocompatibility complex class II-presented epitope repertoire in human monocyte-derived dendritic cells.

Authors:  Rachel M Stenger; Hugo D Meiring; Betsy Kuipers; Martien Poelen; Jacqueline A M van Gaans-van den Brink; Claire J P Boog; Ad P J M de Jong; Cécile A C M van Els
Journal:  Clin Vaccine Immunol       Date:  2014-03-05

4.  Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model.

Authors:  J B Bruss; G R Siber
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

5.  Identification and characterization of heparin binding regions of the Fim2 subunit of Bordetella pertussis.

Authors:  C A Geuijen; R J Willems; P Hoogerhout; W C Puijk; R H Meloen; F R Mooi
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

Review 6.  Acellular pertussis vaccines.

Authors:  E Miller
Journal:  Arch Dis Child       Date:  1995-11       Impact factor: 3.791

7.  Fimbriae and determination of host species specificity of Bordetella bronchiseptica.

Authors:  E H Burns; J M Norman; M D Hatcher; D A Bemis
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

8.  Protective activities in mice of monoclonal antibodies against pertussis toxin.

Authors:  H Sato; Y Sato
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

9.  Effects of guanidinium hydrochloride on the structure and immunological properties of Bordetella pertussis fimbriae.

Authors:  A M Pearce; L I Irons; A Robinson; R N Seabrook
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

10.  Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis.

Authors:  Yinghua Xu; Yaying Wang; Yajun Tan; Huajie Zhang; Lijie Wu; Lichan Wang; Qiming Hou; Shumin Zhang
Journal:  BMC Microbiol       Date:  2009-12-29       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.